Add group to favorites
Back to post list
Send new message to group Search:
Post Subject:
World Pharma News Digest - 20.02.2008
World Pharma News Digest - 20.02.2008
2nd Annual Pharma Corporate Communications Conference
9th & 10th April, 2008
Rome, Italy
The modern business world is based on communication. Corporate
communication is used to shape the strategy of the company and
communicate it internally and externally with major stakeholders.
Pharmaceutical industry is a very special case when it comes to
communication with the public.
Read more...
* w w w .worldpharmanews . com /content/view/301/1/
New price reductions for GSK antiretrovirals in the world's poorest
countries
GSK today announced significant new price reductions for its HIV
medicines offered on a not-for-profit basis to the world's poorest
countries. This reduction is the fifth time the company has made a
price reduction as part of its pioneering preferential pricing policy
originally introduced in 1997.
Read more...
* w w w .worldpharmanews . com /content/view/300/1/
Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007
Financial Results
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today reported its financial
results for the three and twelve months ended December 31, 2007. Onyx
reported a net loss of $11.7 million, or $0.21 per share, for the
fourth quarter of 2007 compared to a net loss of $20.7 million, or
$0.47 per share, in the same period in the prior year.
Read more...
* w w w .worldpharmanews . com /content/view/299/1/
Pfizer to present exclusive new survey results on GP interactions with
pharmacists
Ian Hunter, Pharmacy Development Manager at Pfizer confirmed on Friday
that he will be delivering a presentation at the 5th annual Patient
Compliance & Communication conference. It will contain new data
gathered from a study of 400 GP's and their interactions between
pharmacists, the GPs familiarity with MURs and their impact on patient
care.
Read more...
* w w w .worldpharmanews . com /content/view/298/1/
Bayer and Onyx Provide Update on Phase III Trial of Nexavar®
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc.
announced that a Phase III trial evaluating Nexavar® (sorafenib)
tablets in patients with non-small cell lung cancer (NSCLC) was
stopped early following a planned interim analysis, when the
independent Data Monitoring Committee (DMC) concluded that the study
would not meet its primary endpoint of improved overall survival.
Read more...
* w w w .worldpharmanews . com /content/view/297/1/
Trasylol® - One Thousand Lives A Month
A renowned researcher estimates that 22,000 patients could have been
saved if the Food and Drug Administration removed the heart surgery
drug Trasylol two years ago. Scott Pelley reports.
CBSNews . com
Read more...
* w w w .worldpharmanews . com /content/view/296/1/
World Pharma News . net / Published News:
Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007
Financial Results
* w w w .worldpharmanews . net /Financial/Onyx Pharmaceuticals Reports Fourth=
Quarter and Twelve-Month 2007 Financial Results/
Novartis CEO Dan Vasella: Less Pay for Lower Performance
* w w w .worldpharmanews . net /Blogs/Novartis CEO Dan Vasella Less Pay for L=
ower Performance/
Novartis to cut 2,500 jobs worldwide by 2010
* w w w .worldpharmanews . net /Corporate/Novartis to cut 2500 jobs worldwide=
by 2010/
Bayer and Onyx Provide Update on Phase III Trial of Nexavar
* w w w .worldpharmanews . net /ClinicalTrials/Bayer and Onyx Provide Update =
on Phase III Trial of Nexavar%AE/
Drug Injury Watch: Dr. Dennis Mangano Says On 60 Minutes In February
2008 That Trasylol Should Have Been Recalled As Early As January 2006
* w w w .worldpharmanews . net /Blogs/Drug Injury Watch Dr- Dennis Mangano Sa=
ys On 60 Minutes In February 2008 That Trasylol Should Have Been Recalled As=
Early As January 2006/
EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to
GlaxoSmithKline
* w w w .worldpharmanews . net /Financial/EUSA Pharma Out-Licenses Preclinica=
l-Stage Human Antibody to GlaxoSmithKline/
Trasylol - One Thousand Lives A Month
* w w w .worldpharmanews . net /Product/Trasylol%AE - One Thousand Lives A Mo=
nth/
PharmaGossip: Bayer - Trasylol: one thousand lives a month
* w w w .worldpharmanews . net /Product/PharmaGossip Bayer - Trasylol one tho=
usand lives a month/
FDA grants fast track designation for Boehringer Ingelheim's BIBW 2992
* w w w .worldpharmanews . net /ClinicalTrials/FDA grants fast track designat=
ion for Boehringer Ingelheims BIBW 2992/
Courageous Sanity Triumphs Over Political Inanity (DrugWonks)
* w w w .worldpharmanews . net /Blogs/Courageous Sanity Triumphs Over Politic=
al Inanity DrugWonks/
2nd Annual Pharma Corporate Communications Conference
9th & 10th April, 2008
Rome, Italy
The modern business world is based on communication. Corporate
communication is used to shape the strategy of the company and
communicate it internally and externally with major stakeholders.
Pharmaceutical industry is a very special case when it comes to
communication with the public.
Read more...
* w w w .worldpharmanews . com /content/view/301/1/
New price reductions for GSK antiretrovirals in the world's poorest
countries
GSK today announced significant new price reductions for its HIV
medicines offered on a not-for-profit basis to the world's poorest
countries. This reduction is the fifth time the company has made a
price reduction as part of its pioneering preferential pricing policy
originally introduced in 1997.
Read more...
* w w w .worldpharmanews . com /content/view/300/1/
Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007
Financial Results
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today reported its financial
results for the three and twelve months ended December 31, 2007. Onyx
reported a net loss of $11.7 million, or $0.21 per share, for the
fourth quarter of 2007 compared to a net loss of $20.7 million, or
$0.47 per share, in the same period in the prior year.
Read more...
* w w w .worldpharmanews . com /content/view/299/1/
Pfizer to present exclusive new survey results on GP interactions with
pharmacists
Ian Hunter, Pharmacy Development Manager at Pfizer confirmed on Friday
that he will be delivering a presentation at the 5th annual Patient
Compliance & Communication conference. It will contain new data
gathered from a study of 400 GP's and their interactions between
pharmacists, the GPs familiarity with MURs and their impact on patient
care.
Read more...
* w w w .worldpharmanews . com /content/view/298/1/
Bayer and Onyx Provide Update on Phase III Trial of Nexavar®
Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc.
announced that a Phase III trial evaluating Nexavar® (sorafenib)
tablets in patients with non-small cell lung cancer (NSCLC) was
stopped early following a planned interim analysis, when the
independent Data Monitoring Committee (DMC) concluded that the study
would not meet its primary endpoint of improved overall survival.
Read more...
* w w w .worldpharmanews . com /content/view/297/1/
Trasylol® - One Thousand Lives A Month
A renowned researcher estimates that 22,000 patients could have been
saved if the Food and Drug Administration removed the heart surgery
drug Trasylol two years ago. Scott Pelley reports.
CBSNews . com
Read more...
* w w w .worldpharmanews . com /content/view/296/1/
World Pharma News . net / Published News:
Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007
Financial Results
* w w w .worldpharmanews . net /Financial/Onyx Pharmaceuticals Reports Fourth=
Quarter and Twelve-Month 2007 Financial Results/
Novartis CEO Dan Vasella: Less Pay for Lower Performance
* w w w .worldpharmanews . net /Blogs/Novartis CEO Dan Vasella Less Pay for L=
ower Performance/
Novartis to cut 2,500 jobs worldwide by 2010
* w w w .worldpharmanews . net /Corporate/Novartis to cut 2500 jobs worldwide=
by 2010/
Bayer and Onyx Provide Update on Phase III Trial of Nexavar
* w w w .worldpharmanews . net /ClinicalTrials/Bayer and Onyx Provide Update =
on Phase III Trial of Nexavar%AE/
Drug Injury Watch: Dr. Dennis Mangano Says On 60 Minutes In February
2008 That Trasylol Should Have Been Recalled As Early As January 2006
* w w w .worldpharmanews . net /Blogs/Drug Injury Watch Dr- Dennis Mangano Sa=
ys On 60 Minutes In February 2008 That Trasylol Should Have Been Recalled As=
Early As January 2006/
EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to
GlaxoSmithKline
* w w w .worldpharmanews . net /Financial/EUSA Pharma Out-Licenses Preclinica=
l-Stage Human Antibody to GlaxoSmithKline/
Trasylol - One Thousand Lives A Month
* w w w .worldpharmanews . net /Product/Trasylol%AE - One Thousand Lives A Mo=
nth/
PharmaGossip: Bayer - Trasylol: one thousand lives a month
* w w w .worldpharmanews . net /Product/PharmaGossip Bayer - Trasylol one tho=
usand lives a month/
FDA grants fast track designation for Boehringer Ingelheim's BIBW 2992
* w w w .worldpharmanews . net /ClinicalTrials/FDA grants fast track designat=
ion for Boehringer Ingelheims BIBW 2992/
Courageous Sanity Triumphs Over Political Inanity (DrugWonks)
* w w w .worldpharmanews . net /Blogs/Courageous Sanity Triumphs Over Politic=
al Inanity DrugWonks/
